Cite
HARVARD Citation
Arceci, R. et al. (2017). A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatric blood & cancer. 64 (5), p. n/a. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Arceci, R. et al. (2017). A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis. Pediatric blood & cancer. 64 (5), p. n/a. [Online].